The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care, abiraterone acetate plus prednisone or prednisolone1 The results demonstrate significant and clinically meaningful benefits of the niraparib and abiraterone acetate plus prednisone or prednisolone regimen in delaying cancer progression and worsening of symptoms1

Open call for innovation to help accelerate promising artificial intelligence (AI) solutions that target pressing challenges in surgery NVIDIA and Amazon Web Services (AWS) will join committee to evaluate and select awardees Effort builds on work within J&J MedTech’s Polyphonic™ Digital Ecosystem to provide AI innovation a path into ORs globally

World’s leading* contact lens brand ACUVUE brings pioneering innovation for astigmatic patients with presbyopia, providing visual clarity and comfort2 Launch reinforces Johnson & Johnson’s position as world leader in contact lenses* – pushing boundaries in optical and material science

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease interception1 Recommendation backed by results from the Phase 3 AQUILA study, which demonstrate that daratumumab has the potential to significantly delay the onset of myeloma and the need for treatment, as well as to extend overall survival2

Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients1, 2 Positive opinion reinforces Phase 3 TRIANGLE study results by the European MCL Network, showing ibrutinib plus chemotherapy delivers significantly improved overall survival without the burden of transplant1,2

These additions to the VOLT™ portfolio are anatomically designed1* for two of the most commonly fractured bones2,3

Supported by 52-week data from the Phase 3 UNITI-Jr study, submission aims to expand STELARA® indication to treat children two years of age and older

The new full visual range*1 IOL enables 93% of patients to become free from glasses at all distances.**2 *** With best-in-class image contrast and low-light performance,#~3,4,5 TECNIS Odyssey IOL expands the Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs. TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes.∫7,15

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs